Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of SYH2072 in primary aldosteronism
CTR20264016Phase 2Active
- Sponsor
- Yishi Pharma
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of SYH2072 in primary aldosteronism (PA), sponsored by Yishi Pharma. Started Oct 2026; status: active.
02
Drugs
SYH2072
03
Conditions
primary aldosteronism (PA)
Beyond the preview
Go deeper on CTR20264016.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20264016.